cold chain comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or inert plastic | Compatibility depends on peptide and solvent |
| Headspace gas | Nitrogen or argon | Used to limit oxygen exposure |
| Common reconstitution solvent | Water or buffered aqueous solution | Organic co-solvents may be needed for hydrophobic peptides |
| Freeze-thaw stability | Varies by peptide | Aliquoting reduces repeated cycles |
| Documentation | Lot, date, concentration, storage location | Supports traceability and reproducibility |
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
If there are to be multiple ICP-MS instruments running for long periods of time, then it will most likely be beneficial for the laboratory to install a bulk or micro bulk argon tank which will be maintained by a gas supply company, thus eliminating the need to change out tanks frequently as well as minimizing loss of argon that is left over in each used tank as well as down time for tank changeover. Helium can be used either in place of, or mixed with, argon for plasma generation. Helium's higher first ionisation energy allows greater ionisation and therefore higher sensitivity for hard-to-ionise elements. The use of pure helium also avoids argon-based interferences such as ArO. However, many of the interferences can be mitigated by use of a collision cell, and the greater cost of helium has prevented its use in commercial ICP-MS.
=== Children === There is less evidence for specific transfusion thresholds in children compared to adults. There has only been one randomized trial assessing different thresholds in children, and this showed no difference between a restrictive or liberal transfusion strategy. This trial used similar thresholds to the adult studies, and transfusing when the hemoglobin is less than 70 g/L is also recommended in children.
It is assumed that the ability to respond to insulin-induced hypoglycemia translates into appropriate cortisol rise in the stressful event of acute illness or major surgery. The extreme hypoglycemic version of the ITT is potentially very dangerous and must be undertaken with great care, because it can iatrogenically induce the equivalent of a diabetic coma. A health professional must attend it at all times. Other provocation tests which cause much less release of growth hormone include the use of glucagon, arginine and clonidine.
Sources: en.wikipedia.org
== Pathogenesis == B. cereus is responsible for a minority of foodborne illnesses (2–5%), causing severe nausea, vomiting, and diarrhea. Bacillus foodborne illnesses occur when B. cereus spores or bacteria contaminate food and are allowed to survive cooking, and then given sufficient time to germinate, multiply, and produce toxins in the food. Normal cooking methods such as boiling, stewing, or steaming at 100 °C (212 °F) reliably kill Bacillus cereus vegetative cells, but do not reliably destroy heat-resistant spores. The risk is increased when cooked food is then slowly cooled or left within the temperature "danger zone", which is between 4 °C (39 °F) to 60 °C (140 °F), allowing spores to germinate. FDA's Food Code 2017 recommends that cooked food not meant for immediate consumption is cooled rapidly and refrigerated promptly at temperatures below 5 °C (41 °F), or is kept hot above 57 °C (135 °F). Refrigeration does not destroy bacteria but inhibits or slows their growth. Germination and growth generally occur between 10 °C and 50 °C, though some strains can grow at low temperatures, and Bacillus cytotoxicus strains have been shown to grow at temperatures up to 52 °C (126 °F). Bacterial growth results in production of enterotoxins, one of which is highly resistant to heat and acids (pH levels between 2 and 11); ingestion leads to two types of illness: diarrheal and emetic (vomiting) syndrome. The enterotoxins produced by B. cereus have beta-hemolytic activity.
Many small studies using small doses, often half the recommended dose, have not shown much effect, but these cannot be relied upon to give much information on the more common practice of step-wise therapy and slow dose escalation. Chronic opioid use predictably leads to tolerance, and may do so fairly quickly, in days to weeks. This occurs even with what are considered modest doses, e.g. ≥25mg oxycodone a day. This may result in the patient to need higher and/or more frequent doses of the drug to get euphoric effects, although it may not be a factor in analgesic effects as tolerance to a dose of opioid does not seem related to loss of efficacy. Tolerance is associated with upregulation of μ-receptors, and possibly others. Concentration-dependence adverse effects may vary based on the user's genetic polymorphisms which can alter drug metabolism. Cytochrome P450, notably CYP2D6, but also CYP3A4, is responsible for the metabolism of various opiates to active metabolites and variations in CYP450 activity lead to varying serum drug levels.
== Manufacturing == Remdesivir requires "70 raw materials, reagents, and catalysts" to make, and approximately "25 chemical steps." Some of the ingredients are extremely dangerous to humans, especially trimethylsilyl cyanide. The original end-to-end manufacturing process required 9 to 12 months to go from raw materials at contract manufacturers to finished product, but after restarting production in January 2020, Gilead Sciences was able to find ways to reduce the production time to six months. In January 2020, Gilead began working on restarting remdesivir production in glass-lined steel chemical reactors at its manufacturing plant in Edmonton, Alberta. On 2 February 2020, the company flew its entire stock of remdesivir, 100 kilograms in powder form (left over from Ebola research), to its filling plant in La Verne, California, to start filling vials. The Edmonton plant finished its first new batch of remdesivir in April 2020. Around the same time, fresh raw materials began to arrive from contract manufacturers reactivated by Gilead in January. Another challenge is getting remdesivir into patients despite the drug's "poor predicted solubility and poor stability." In June 2020, Ligand Pharmaceuticals revealed that Gilead has been managing those issues by mixing Ligand's proprietary excipient Captisol (based on University of Kansas research into cyclodextrin) with remdesivir at a 30:1 ratio.
== History == The British computer scientist Alan Turing laid the theoretical groundwork for artificial intelligence. His foundational 1936 paper on the Entscheidungsproblem introduced the concept of the universal computing machine. Turing's wartime efforts at Bletchley Park involved developing the Bombe, an electromechanical device that utilized heuristic search techniques to decipher Enigma codes. In 1950, Turing published his seminal paper "Computing Machinery and Intelligence" in the journal Mind, where he proposed the "Imitation Game" (now known as the Turing Test) as a criterion for machine intelligence. This period established Britain as a global leader in early computational theory and machine intelligence. During the 1960s, the UK established AI research centers, most notably at the University of Edinburgh. In 1963, Donald Michie founded a small research group that later evolved into the Department of Machine Intelligence and Perception. Michie's team developed the Freddy robots (Freddy I and Freddy II), which were early examples of robots capable of integrating vision and manipulation to assemble objects. Researchers such as Robert Kowalski at the University of Edinburgh and later Imperial College London made significant contributions to logic programming, laying the theoretical foundations for the Prolog programming language. However, the optimism of the 1960s was curtailed by the 1973 Lighthill Report.
Sources: en.wikipedia.org
== External links == GMP+synthetase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) PDBe-KB provides an overview of all the structure information available in the PDB for Human GMP synthase [glutamine-hydrolyzing]
ACS Applied Materials & Interfaces. 16 (12): 14633–14644. Bibcode:2024AAMI...1614633K. doi:10.1021/acsami.4c02243. PMC 10982941. PMID 38483312. Karki, Sandeep; Malhotra, Sahil; Ijaz, Muhammad; Rollet, Nicolas; O'Cearbhaill, Eoin D.; Bini, Estela; Brayden, David J. (2026). "A pullulan-based bilayer film for buccal delivery of a GLP-1 peptide analogue". Carbohydrate Polymers. 380 125064. doi:10.1016/j.carbpol.2026.125064. PMID 41831981.
=== Sensitivity === Another key aspect of GC x GC that can be highlighted is that the result from the refocusing in the 2D, which occurs during the modulation, causes a significant increase in sensitivity, when thermal modulators are used. The modulation process causes the chromatographic bands in GC × GC systems are 10-50 times closer than in 1D-GC, resulting in values for much better peak widths (FWHM Full Width Half Mass) between 50 ms to 500 ms, which requires detectors with fast response and small internal volumes. When traditional flow modulators are used, the higher flows used to release the analytes from the trap have a diluting effect and do not produce an increase in sensitivity (GC × GC-FID) in concentration-dependant detectors (e.g. ECD), however there can be an increase in mass-dependant detectors such as FID. As most mass spectrometers cannot handle higher flows from flow modulation a splitting device often needs to be used, greatly reducing the amount of material reaching the MS (1/10th to 1/20th), thus causing a further loss of sensitivity.
On 5 January 2026, the Venezuelan government issued an emergency order to police to arrest anyone who supported the US attack and mobilized colectivos (pro-government paramilitaries) who established roadblocks and searched cars and people. Fourteen journalists were detained, but 13 of them were later released. On 6 January, gunfire broke out in Caracas as the ministry of communication announced that police fired upon one of their own military drones "flying without permission" but that the drone suffered no damage.
Label-free quantification is a method in mass spectrometry that aims to determine the relative amount of proteins in two or more biological samples. Unlike other methods for protein quantification, label-free quantification does not use a stable isotope containing compound to chemically bind to and thus label the protein.
Sources: en.wikipedia.org
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.
Aliquoting divides a solution into smaller portions so that each portion is handled once. This reduces repeated freeze-thaw cycles and limits contamination risk. It also makes it easier to track usage and maintain consistent test conditions.
Refreezing is possible for some peptides but can promote aggregation or precipitation. The effect depends on the peptide, solvent, concentration, and freezing rate. Many laboratory protocols therefore recommend single-use aliquots instead of repeated refreezing.
Work quickly in a dry environment and keep the container closed when not in use. Equilibrate sealed vials to room temperature before opening to reduce condensation. Record mass changes, as absorbed water can affect concentration calculations.